Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

0.3004 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio
Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of... 
Via Benzinga
Marijuana Stock Movers For July 31, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 28, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 25, 2023
Via Benzinga
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
SciSparc To Conduct Clinical Trial For Dronabinol-Based Drug To Treat Tourette Syndrome In Germany
SciSparc Ltd. (NASDAQ: SPRC) has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its phase IIb clinical trial to use SCI-110 for treating... 
Via Benzinga
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
From SciSparc Ltd
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on! 
Via InvestorPlace
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
EXCLUSIVE: SciSparc's Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US
SciSparc Ltd (NASDAQ: SPRC) has received Institutional Review Board (IRB) approval for its Phase 2b clinical trial for SCI-110 in subjects suffering from Tourette Syndrome. Tourette Syndrome is a... 
Via Benzinga
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd. 
Via Benzinga
The 7 Most Promising Penny Stocks to Buy in June
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher. 
Via InvestorPlace
SciSparc Nutraceuticals Granted An Exclusive License For The Sales Of CannAmide On The Amazon Marketplace In Canada
Jeffs' Brands Ltd (NASDAQ: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, announced that SciSparc Nutraceuticals Inc., in which the company owns a 49% equity interest, has... 
Via Benzinga
Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada
From Jeffs' Brands Ltd
Via GlobeNewswire
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
From SciSparc Ltd
Via GlobeNewswire
Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes
NCIA Sacks Half Of Its Team To Increase Financial Strength 
Via Benzinga
New Drug Based On FDA-Approved Synthetic THC And CannAmide Shows Promise In Treating Agitation In Alzhemier's
SciSparc Ltd. 
Via Benzinga
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitation 
From SciSparc Ltd
Via GlobeNewswire
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
From SciSparc Ltd
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a hot topic on Monday as we dive into the biggest winners and losers traders need to know about this morning! 
Via InvestorPlace
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program
From SciSparc Ltd
Via GlobeNewswire
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
From SciSparc Ltd
Via GlobeNewswire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Why SAP Shares Are Trading Higher By Around 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Mangoceuticals, Inc. (NASDAQ: MGRX) shares jumped 207% to $2.84. The company announced Thursday, that it's featured on Webull Corporate Communications Service Platform. 
Via Benzinga
SciSparc And Clearmind Collaboration Strengthens IP Portfolio With Patent Application For Treatment Of Depression
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
Clearmind Medicine Expanding IP Portfolio with New US Patent Application for Treatment of Depression
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Patent Application in the U.S. for Treatment of Depression
From SciSparc Ltd
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.